Emerging life sciences companies know well the first valley of death that is encountered - securing initial investment to translate an early medical device concept to a development stage that is attractive to institutional investors and strategic partners. Many in the life sciences community believe - at their own peril - that once this valley is crossed that the biggest challenge has been conquered. Unfortunately, many companies encounter the second valley of death when they find that their development strategy has focused only on regulatory approval to the neglect of designing for reimbursement acceptance.
Morris, Manning & Martin, LLP together with Georgia Bio and SEMDA will bring together a panel of experts to share their experience on the role of reimbursement strategy for the success of the emerging medical device company.
- Bob Crutchfield, General Partner, Harbert Growth Partners
- Richard Dimonda, Co-Founder, Sensory Innovations
- Jack Gerhart, Consultant, Medical Device Business Strategy
- Michele Madison, Partner, Morris, Manning & Martin, LLP
- MODERATOR: Mary An Merchant, Life Sciences Chair, Morris, Manning & Martin, LLP